...
首页> 外文期刊>Journal of Ginseng Research >Safety and tolerability of Korean Red Ginseng in healthy adults: a multicenter, double-blind, randomized, placebo-controlled trial
【24h】

Safety and tolerability of Korean Red Ginseng in healthy adults: a multicenter, double-blind, randomized, placebo-controlled trial

机译:高丽红参在健康成人中的安全性和耐受性:一项多中心,双盲,随机,安慰剂对照试验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Korean Red Ginseng (KRG) has been used in Asia for its various biological effects, but no studies have investigated the safety of its long-term intake. Therefore, the present study evaluated the safety of KRG intake for 24 weeks. Methods We randomized 1,000 participants in a 1:1 ratio into two groups, which were treated daily with 2?g of KRG or a placebo?for 24 weeks. The primary endpoint was all adverse events and adverse drug reactions (ADRs) that occurred after KRG or placebo administration, which were reported at week 4, 12, and 24 after the baseline visit. Results In total, 192 and 211 participants experienced adverse events in the KRG and placebo groups (39.2% and 42.0%, respectively; p =?0.361), and 59 and 57 KRG- and placebo-treated individuals reported ADRs (12.0% and 11.4%, respectively; p =?0.737). The frequently occurring ADRs were pruritus (2.0%), headache (1.6%), diarrhea (1.4%), and dizziness (1.2%) in the KRG group and pruritus (2.0%), headache (1.8%), dizziness (1.6%), rash (1.4%), and diarrhea (1.2%) in the placebo group. Discontinuation of drug administration due to ADRs was reported in 13 participants, six (1.2%) and seven (1.4%) in the KRG and placebo groups, respectively ( p =?0.814). No significant abnormal changes were revealed by anthropometric, laboratory, and vital sign measurements in the KRG group compared with those in the placebo group. Conclusion The present study confirms the safety and tolerability of daily intake of 2?g of KRG for 24 weeks by healthy adults.
机译:背景技术韩国红参(KRG)因其多种生物学作用而在亚洲得到使用,但没有研究对其长期摄入的安全性进行研究。因此,本研究评估了24周内摄入KRG的安全性。方法我们以1:1的比例将1,000名参与者随机分为两组,每天接受2微克KRG或安慰剂治疗24周。主要终点是所有在KRG或安慰剂给药后发生的不良事件和药物不良反应(ADR),在基线访视后第4、12和24周进行了报道。结果总共有192和211名参与者在KRG和安慰剂组中经历了不良事件(分别为39.2%和42.0%; p =?0.361),分别有59和57名接受KRG和安慰剂治疗的人报告了ADR(分别为12.0%和11.4) %; p =≤0.737)。 KRG组中常见的ADR为瘙痒(2.0%),头痛(1.6%),腹泻(1.4%)和头晕(1.2%),瘙痒(2.0%),头痛(1.8%),头晕(1.6%) ),安慰剂组的皮疹(1.4%)和腹泻(1.2%)。据报道,有13名受试者因ADR停止给药,在KRG和安慰剂组中分别有6名(1.2%)和7名(1.4%)(p =?0.814)。与安慰剂组相比,KRG组的人体测量,实验室检查和生命体征测量均未发现明显的异常变化。结论本研究证实了健康成年人每天摄入2微克KRG 24周的安全性和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号